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included	 baseline	 characteristics,	 neoadjuvant	 therapy,	 imaging	 protocols,	 local	 regrowth,	 distant	






























total	 mesorectal	 excision	 and	 neoadjuvant	 (chemo-)radiotherapy.1	 However,	 this	 treatment	 remains	
associated	with	perioperative	mortality	of	2%	and	up	to	four	times	higher	in	the	elderly.2,3	In	addition,	it	











response	 (cCR)	 after	 neoadjuvant	 chemoradiotherapy	 by	 Habr-Gama,7	 multiple	 cohort	 series	 are	 now	
available	in	which	surgery	has	been	omitted.8-11	It	is	known	that	the	diagnosis	of	a	cCR	based	on	the	results	
of	 conventional	 imaging	modalities	does	not	perfectly	correspond	 to	a	 true	CR,	as	 local	 regrowth	rates	
within	2	years	of	follow	up	range	from	7	to	33%.12,13	Despite	local	tumour	regrowth	rates,	the	results	so	far	





surgical	 oncology	 guidelines.	 Most	 available	 cohort	 series	 are	 small	 and	 have	 heterogeneous	 study	




























patient	 data	 registry.	Data	 entry	 is	 performed	online	 at	 participating	centres	 under	 supervision	 of	 the	
participating	investigator,	and	stored	in	a	highly	secured	NEN7510	certified	and	encrypted	research	data	
server	(ProMISe).15	The	IWWD	database	contains	information	on	patient	and	tumour	characteristics	at	the	
time	 of	 diagnosis,	 the	 reason	 for	 organ-preserving	 treatment,	 type	 of	 neoadjuvant	 therapy,	 results	 of	
imaging	modalities	 at	 diagnosis,	 reassessment	 after	 neoadjuvant	 therapy	 and	 follow-up,	 details	 of	 the	
treatment	for	disease	recurrence,	and	survival	status.	All	assessments	were	done	according	to	local	W&W	




















rate	 in	 the	 present	 study.	 Furthermore,	 overall	 survival	 (OS)	 and	 disease-specific	 survival	 (DSS)	were	

















The	 funders	 had	no	 role	 in	 the	 study	design,	 data	analysis	 or	writing	 the	 report.	 The	members	 of	 the	
















































resection	 subsequently.	 In	 total	 115	patients	 underwent	TME	 resection	 for	 local	 regrowth	 (77·7%),	 of	
which	99·1%	with	curative	intention.	In	87·8%	of	all	surgical	resections	for	local	regrowth,	the	resection	










Distant	metastasis	were	most	 frequently	 located	in	 lungs	 (62·0%),	 followed	by	 liver	 (40·8%).	Thirteen	
patients	(18·3%)	were	diagnosed	with	lung	and	liver	metastasis	simultaneously.	Other	locations	of	distant	
metastasis	were	distant	lymph	nodes	(11·3%)	and	peritoneum	(5·6%).		
In	 patients	 with	 local	 regrowth,	 the	 incidence	 of	 distant	 metastasis	 was	 17·8%	 (38/213),	 whereas	 in	
patients	with	a	sustained	complete	response	this	was	4·9%	(33/634).	Of	the	patients	with	both	distant	








(95%CI	 83·8-91·0).	 For	 patients	 that	were	 diagnosed	with	 local	 regrowth,	 the	 5-year	 DSS	 was	 84·0%	
(95%CI	75·0-89·9)	and	5-year	OS	75·4%	(95%CI	66·2-82·4).	



















































labeled	pCR	 if	 they	would	have	had	TME	surgery	after	 the	chemoradiation.	 It	 is	well	documented	 that	























frequent	endoscopic	 surveillance	 in	W&W	patients	 in	 the	 first	 two	years	of	 follow-up,	 the	 location	and	
incidence	of	distant	metastasis	and	the	small	risk	of	incurable	disease.	However,	many	uncertainties	and	
clinical	 challenges	 remain.	 Importantly,	 long-term	 quality	 of	 life	 outcomes,	 and	 effects	 of	
(chemo)radiotherapy	on	bowel	function	in	W&W	patients	are	still	unknown.	As	the	percentage	of	cancer	







we	aim	 to	 improve	 the	estimation	 of	 individualized	 risks,	 and	 to	 aid	 shared-decision	making	 between	
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Table	1:	Patient	characteristics	at	baseline	
Data	are	displayed	as	n(%),	unless	indicated	otherwise.		
BMI=body	mass	index	
	
		 	 N=880	(%)	
Age	 Mean	(SD)	 63.6	(11·7)	
BMI	 Mean	(SD)	 26.7	(4·9)	
Sex	 Male	
Female	
603	(68·5)	
277	(31·5)	
Comorbidity		
	
	
yes	
no	
unknown	
252	(28·6)	
337	(38·3)	
273	(33·1)	
Country	 Argentina	
Belgium	
Brazil	
Germany	
Denmark	
France	
Great	Britain	
Ireland	
the	Netherlands	
Poland	
Portugal	
Russia	
Sweden	
Turkey	
46	(5·2)	
27	(3·1)	
201	(22·8)	
25	(2·8)	
40	(4·5)	
42	(4.8)	
150	(17·0)	
35	(4·0)	
252	(28·6)	
15	(1·7)	
21	(2·4)	
5	(0·6)	
15	(1·7)	
6	(0·7)	
Year	of	
decision	for	
W&W	
Before	2010	
2010-2014	
2015	-	present	
177	(20·2)	
450	(51·1)	
253	(28·8)	
clinical	T	
stage	baseline	
cT1	
cT2	
cT3	
cT4	
unknown	
14(1·6)	
226	(25·7)	
451	(51·3)	
30	(3·4)	
159	(18·1)	
clinical	N	
stage	baseline	
cN0	
cN1	
cN2	
unknown	
309	(35·1)	
271	(30·8)	
167	(19·0)	
133	(15·1)	
Last	study	
status	
In	follow-up	
Follow-up	completed	
Lost	to	follow-up	
Deceased	
660	(75·0)	
57	(6·5)	
64	(7·3)	
99	(11·3)	
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Table	2:	Diagnostic	procedures	at	baseline	and	at	reassessment	after	induction	therapy.		
Data	are	displayed	as	n(%).		
	
	 Baseline:	n	(%)	 Reassessment:	n	(%)	
Endoscopy		 848	(96·4)	 779	(88·5)	
MRI	pelvis	 678	(77·0)	 620	(70·5)	
CT	pelvis	 378	(43·0)	 261	(29·7)	
Endorectal	ultrasound	 146	(16·6)	 67	(7·6)	
PET	scan		 116	(13·2)	 39	(4·4)	
CEA	 540	(61·4)	 196	(22·3)	
Local	excision	
ypT0	
ypT+	
-	
45	(5·0)	
40	
5	
	
	
Table	3:	Different	types	and	combinations	of	induction	therapy		
Data	are	displayed	as	frequencies	(n).	
CRT=	Chemo-radiotherapy,	BRT=	Brachy	radiotherapy,	EBT=	External-beam	radiotherapy,	CT=	Chemotherapy.		
	
Single	therapy	 n	
	 Chemo-radiotherapy	(CRT)		 738	
	 Brachy	radiotherapy	(BRT)	 5	
	 External	beam	radiotherapy	(EBT)	 35	
	 Chemotherapy(CT)		 3	
	 Total	 781	
	 	 	
Different	combinations	 	
	 CRT	+	BRT		 57	
	 CRT+	CT	 7	
	 BRT+	EBT	 19	
	 EBT+	CT	 7	
	 CRT+	BRT+	EBT	 2	
	 Total		 92	
Missing	 	 7		
Total	 	 880	
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